Allurion Technologies, Inc. develops treatments for obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, a swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The company was founded on January 25, 2023 and is headquartered in Natick, MA.
Allurion Technologies startet eine Studie seines Magenballons in Verbindung mit GLP-1-Produkten, die zu einem besserem Erhalt der Muskelmasse führen soll.
Allurion Technologies (ALUR) hat am Donnerstag, den 23. Januar 2025, eine Pressemitteilung veröffentlicht und in dieser seine Pläne zur Optimierung der Muskelmasse während...
Wir finden für unsere Leser softwaregestützt die besten Aktien der Welt und schreiben darüber, wie man diese handeln muss, um Geld zu verdienen.
